Company / Return on Equity (ROE)
Nuo Therapeutics, Inc. Return on Equity (ROE) History
FY2011-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-3102.0%
FY2017
5-year range
-3102.0% / -45.6%
FY2013-FY2017
Trend
-6699.7%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Nuo Therapeutics, Inc. reports negative total equity of -3102.0% in FY2017. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-3102.0% in FY2017 with a 5-year CAGR of -3049.9%.
Declined from -122.1% to -3102.0% over the past 3 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -2979.9pp
- 5-Year Change
- -3049.9pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2017, return on equity (roe) decreased 6699.7% year-over-year.
- Peak return on equity (roe) was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -45.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2017 | -3102.0% | -6699.7% |
| FY2016 | -45.6% | - |
| FY2015 | - | - |
| FY2014 | -122.1% | -58.6% |
| FY2013 | -77.0% | -47.7% |
| FY2012 | -52.1% | +51.3% |
| FY2011 | -107.0% | - |
As of FY2017 · SEC 10-K · Updated Jun 29, 2026